98%
921
2 minutes
20
Exploring regimens to facilitate microglia transformation from M1 to M2 phenotype is a feasible strategy to suppress neuroinflammation, therefore reinforcing functional recovery after ischemic stroke. Muscone easily crosses the blood brain barrier (BBB) and distributes throughout the brain. Here, the results illustrated the administration of 8 mg/kg muscone promoted functional recovery through reducing the infarct volume by 2,3,5-triphenyltetrazolium chloride (TTC) staining after ischemic stroke in mice. Then, the expression of pro-inflammatory factors, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6), was significantly decreased, whereas the level of anti-inflammatory agents including C-X-C Motif Chemokine Ligand 1 (CXCL1), transforming growth factor-β (TGF-β) and interleukin-10 (IL-10) was obviously elevated in penumbra with the treatment of 8 mg/kg muscone using real-time fluorescence quantitative polymerase chain reaction (RT-qPCR), western blot and enzyme-linked immunosorbent assay (ELISA) tests. Subsequently, the results showed the application of muscone upregulated the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) to facilitate microglia transformation into M2 phenotype using RT-qPCR, western blot and immunofluorescence analysis. Collectively, the present study provides evidence for our hypothesis that muscone intensifies microglia transformation into M2 phenotype via activating PPAR-γ signaling pathway in penumbra after ischemic stroke. These findings demonstrate muscone is a promising candidate for the treatment of ischemic stroke.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cellimm.2023.104704 | DOI Listing |
Clin Investig Arterioscler
September 2025
Cardiovascular Biochemistry, IR SANT PAU, Barcelona, Spain; CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Madrid, Spain. Electronic address:
Background: Electronegative LDL (LDL(-)) is a circulant modified LDL with inflammatory properties whose proportion raises in ischemic events. The soluble form of LDL receptor related protein 1 (sLRP1) increases in blood in pathological situations, including ischemic stroke. We aimed to evaluate the effect of LDL(-) on sLRP1 release from monocytes and macrophages.
View Article and Find Full Text PDFIntern Med
September 2025
Department of Infectious Diseases, Fukuoka City Hospital, Japan.
Staphylococcus saprophyticus primarily colonizes the lower gastrointestinal tract; however, infections from this site are rarely reported. A 77-year-old man developed an ischemic stroke and fever. Blood cultures showed S.
View Article and Find Full Text PDFJ Neurointerv Surg
September 2025
Neurology Department, Lariboisière Hospital, APHP, Université Paris Cité, Paris, France.
Background And Purpose: Cervicocephalic artery dissection (CCAD) is a well-recognized cause of ischemic stroke. However, complex forms of CCAD, characterized by a wide intimal inlet without a visible intramural hematoma, pose diagnostic challenges and complicate endovascular access to the true lumen when recanalization is required. We aimed to analyze the clinical presentation, outcomes, and feasibility of endovascular treatment of complex CCAD and to propose a novel morphological classification.
View Article and Find Full Text PDFBMJ Open
September 2025
Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
Introduction: Intracranial atherosclerosis is the main cause of stroke globally, with acute large vessel occlusive (LVO) stroke being a predominant contributor to stroke-related mortality. In recent years, aspiration thrombectomy (AT) has emerged as a novel therapeutic method for treating acute LVO stroke. The purpose of this study aims to investigate the safety and efficacy of AT alone or combined with stent retriever thrombectomy (SRT) in the treatment of acute LVO stroke METHODS AND ANALYSIS: This is a multicentre and observational real-world study involving patients diagnosed with acute LVO stroke.
View Article and Find Full Text PDFJ Thromb Haemost
September 2025
Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA.
Background: Balancing the risks of thrombotic and bleeding events in people with advanced kidney disease is a clinical challenge.
Objectives: To estimate rates of major adverse thrombotic events (MATEs) and bleeding events in individuals with chronic kidney disease (CKD) stages 4 or 5 or with end-stage kidney disease (ESKD) receiving hemodialysis (HD) or peritoneal dialysis (PD).
Methods: Using administrative claims from a 20% Medicare sample, Optum's de-identified Clinformatics Data Mart Database, and the US Renal Data System from 2016-2019, we identified individuals with CKD stages 4 or 5 and individuals with dialysis-dependent ESKD.